TScan Therapeutics price target cut to $1.00 from $5.00
Wedbush cut its price target on TScan Therapeutics to $1.00 per share from $5.00, according to Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.